From: A genome scale overexpression screen to reveal drug activity in human cells
Drug name | Screen concentration | Category* | Clinical use | Known target(s) | Reference |
---|---|---|---|---|---|
Methotrexate | 60 nM | Antimetabolites/ immunosuppressants | Antineoplastic | DHFR | [20] |
Antirheumatic | |||||
Dermatologic agent | |||||
Aminopterin | 20 nM | Antimetabolites (discontinued) | Dermatologic agent (phase I) | DHFR, FPGS(?) | [21] |
Antineoplastic agent (phase II) | |||||
Orlistat | 20 μM | Antiobesity preparations, excluding diet products | Anti-obesity agent | LPL | [22] |
PNLIP | [23] | ||||
FASN | |||||
Bleomycin | 1 μM | Cytotoxic antibiotics and related substances | Antineoplastic agent | DNA | [24] |
LIG1 | |||||
LIG3 | |||||
Cisplatin | 2 μM | Other antineoplastic agents | Antineoplastic agent | DNA | [25] |
Mitomycin C | 80 nM | Cytotoxic antibiotics and related substances | Antineoplastic agent | DNA | [26] |
17_DMAG | 70 nM | Experimental Hsp90 inhibitor | Antineoplastic agent (phases I and II) | Hsp90 | [27] |
HSP90AA1 | |||||
HSP90AA2 | |||||
HSP90B1 | |||||
HSP90AB1 |